Solara Active Pharma Sciences Ltd. (IN:SOLARA)
:SOLARA
Want to see IN:SOLARA full AI Analyst Report?
Top Page
Solara Active Pharma Sciences Ltd.
(SOLARA)
Select Model
Select Model
Rating:52Neutral
Price Target:
₹584.00
▲(0.21% Upside)
Action:Reiterated
Date:06/10/26
The score is held back primarily by uneven financial performance and weakening FY2026 cash flow alongside a net loss, despite improving leverage. Technicals are supportive (price above key moving averages with positive MACD), but valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
API & CDMO business model
Solara's core focus on API manufacturing and contract development/manufacturing serves regulated and semi-regulated markets and is export-driven. That business mix creates recurring supply relationships, customer qualification barriers, and diversified revenue streams, supporting durable demand and long-term contract opportunities.
Negative Factors
Weak cash generation
Cash generation deteriorated sharply in FY2026, with OCF at 617m and free cash flow plunging ~80% to 88.8m. Persistent volatility in cash conversion limits internal funding for capex, R&D and working capital, increases dependence on external financing, and raises execution risk across multi-year API qualification and supply cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
API & CDMO business model
Solara's core focus on API manufacturing and contract development/manufacturing serves regulated and semi-regulated markets and is export-driven. That business mix creates recurring supply relationships, customer qualification barriers, and diversified revenue streams, supporting durable demand and long-term contract opportunities.
Read all positive factors
Solara Active Pharma Sciences Ltd. (SOLARA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹27.10B
Dividend YieldN/A
Average Volume (3M)37.94K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue Growth6.64%
EPS Growth-177.19%
CountryIN
Employees2,156
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.59
Shares Outstanding47,711,830
10 Day Avg. Volume26,889
30 Day Avg. Volume37,944
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.50
Price to Sales (P/S)1.37
P/FCF Ratio211.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31.4
Revenue Forecast (FY)₹17.95B
Solara Active Pharma Sciences Ltd. Business Overview & Revenue Model
Company Description
Solara Active Pharma Sciences Limited is an Indian-based pharmaceutical company primarily involved in the comprehensive development, production, and global trade of active pharmaceutical ingredients (APIs). Their activities span the manufacturing,...
How the Company Makes Money
Solara primarily makes money by selling pharmaceutical ingredients and associated manufacturing services to other drug companies. Key revenue streams include: (1) Sales of generic APIs: Solara manufactures APIs at scale and sells them to pharmaceu...
Solara Active Pharma Sciences Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
58
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.06B | 13.69B | 12.84B | 12.89B | 14.27B | 12.68B |
| Gross Profit | 6.53B | 3.66B | 6.57B | -1.30B | 1.25B | 5.60B |
| EBITDA | 2.04B | 1.87B | 2.06B | -2.82B | 1.52B | 793.30M |
| Net Income | 64.10M | -74.10M | 5.40M | -5.67B | -221.70M | -581.50M |
Balance Sheet | ||||||
| Total Assets | 22.93B | 23.33B | 22.32B | 23.51B | 28.99B | 29.53B |
| Cash, Cash Equivalents and Short-Term Investments | 169.30M | 533.40M | 41.10M | 84.40M | 87.30M | 463.80M |
| Total Debt | 6.46B | 6.87B | 7.96B | 10.12B | 10.13B | 10.37B |
| Total Liabilities | 10.36B | 10.77B | 11.35B | 14.14B | 13.97B | 14.18B |
| Stockholders Equity | 12.55B | 12.53B | 10.94B | 9.34B | 15.00B | 15.25B |
Cash Flow | ||||||
| Free Cash Flow | 454.60M | 88.80M | 1.73B | 678.10M | 449.40M | -4.51B |
| Operating Cash Flow | 740.60M | 617.00M | 2.13B | 1.09B | 1.56B | -2.42B |
| Investing Cash Flow | -273.60M | -998.60M | -368.30M | -35.10M | -811.40M | -2.43B |
| Financing Cash Flow | -469.60M | 386.90M | -1.80B | -1.06B | -1.13B | 3.34B |
Solara Active Pharma Sciences Ltd. Technical Analysis
Positive
582.80
Price Trends
528.63
Positive
502.17
Positive
547.65
Positive
Market Momentum
16.18
Negative
53.58
Neutral
56.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SOLARA, the sentiment is Positive. The current price of 582.8 is above the 20-day moving average (MA) of 561.32, above the 50-day MA of 528.63, and above the 200-day MA of 547.65, indicating a bullish trend. The MACD of 16.18 indicates Negative momentum. The RSI at 53.58 is Neutral, neither overbought nor oversold. The STOCH value of 56.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SOLARA.
Solara Active Pharma Sciences Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹102.41B | 18.41 | ― | 0.41% | 4.88% | 66.43% | |
67 Neutral | ₹37.63B | 27.38 | ― | 0.97% | 11.54% | 36.15% | |
66 Neutral | ₹193.86B | 32.19 | ― | 0.24% | 19.73% | 18.17% | |
59 Neutral | ₹31.59B | 12.48 | ― | ― | 8.53% | 67.93% | |
52 Neutral | ₹27.10B | -334.22 | ― | ― | 6.64% | -177.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ₹24.48B | -50.09 | ― | 0.58% | -7.91% | -153.72% |
* Healthcare Sector Average
IN:SOLARA
Solara Active Pharma Sciences Ltd.
567.95
37.25
7.02%
IN:GRANULES
Granules India Limited
782.35
296.99
61.19%
IN:HIKAL
Hikal Limited
198.50
-159.88
-44.61%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
128.20
43.33
51.05%
IN:STAR
Strides Pharma Science Ltd
1,111.10
288.62
35.09%
IN:UNICHEMLAB
Unichem Laboratories Limited
448.70
-137.90
-23.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.